Procter & Gamble gives 33 patents to US university
Procter & Gamble has donated to the University of Arizona (UA) Foundation 33 patents and accompanying intellectual property related to a portfolio of compounds that have been tested in preclinical studies and may have application in the treatment of cancer, HIV and Hepatitis C.
The portfolio includes the compounds FB636, FB642 and PG-301029. FB642 appears to demonstrate a novel mechanism of action to inhibit the growth of certain cancer cells. In addition, both FB642 and FB636 show promise for the treatment of HIV. PG-301029 is a novel antiviral compound that shows promise for the treatment of Hepatitis C. Preclinical studies suggest that PG-301029's distinctive mechanism of action directly interferes with the production of the Hepatitis C virus.
As the new sole owners of the technology, the UA will benefit from all future revenues if the compounds can be successfully developed and commercialised.
'Our internationally recognized pharmaceutical research team will pursue the development of potentially life-saving treatments,' said Dr J Lyle Bootman, Dean of the UA College of Pharmacy.